Immune Design Corp. (NASDAQ:IMDZ) shares saw strong trading volume on Thursday . 105,953 shares traded hands during trading, an increase of 86% from the previous session’s volume of 56,860 shares.The stock last traded at $6.56 and had previously closed at $6.62.

Several analysts recently commented on the stock. Jefferies Group reissued a “buy” rating and set a $20.00 target price on shares of Immune Design Corp. in a research note on Sunday, May 29th. Zacks Investment Research raised shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research note on Friday, August 12th. Cowen and Company restated a “buy” rating on shares of Immune Design Corp. in a research report on Wednesday, May 11th. Leerink Swann restated a “buy” rating on shares of Immune Design Corp. in a research report on Thursday, May 12th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research report on Wednesday, May 11th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $14.50.

The company’s 50 day moving average is $7.29 and its 200 day moving average is $10.64. The stock’s market capitalization is $138.20 million.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.03. Analysts forecast that Immune Design Corp. will post ($2.70) earnings per share for the current year.

A hedge fund recently raised its stake in Immune Design Corp. stock. Jennison Associates LLC increased its stake in shares of Immune Design Corp. (NASDAQ:IMDZ) by 0.4% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 203,452 shares of the company’s stock after buying an additional 769 shares during the period. Jennison Associates LLC owned 1.01% of Immune Design Corp. worth $4,085,000 as of its most recent filing with the SEC.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.